Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649950 | 0.86 | EGFR (0.56) | EGFRCSNK2A2CSNK2BJAK2JAK1 | |
| SCHEMBL5676295 | 0.86 | EGFR (0.56) | EGFRCSNK2A2CSNK2BJAK2JAK1 | |
| SCHEMBL27881435 | 0.85 | EGFR (0.54) | EGFRCSNK2A2CSNK2BJAK2JAK1 | |
| SCHEMBL12466410 | 0.84 | EGFR (0.53) | EGFRCSNK2A2CSNK2BIMPDH2SMN1; SMN2 | |
| SCHEMBL30533141 | 0.84 | EGFR (0.53) | EGFRCSNK2A2CSNK2BIMPDH2SMN1; SMN2 | |
| SCHEMBL29648005 | 0.84 | EGFR (0.50) | EGFRCSNK2A2CSNK2BJAK2JAK1 | |
| SCHEMBL28850937 | 0.83 | EGFR (0.51) | EGFRCSNK2A2CSNK2BIMPDH2BAZ1A | |
| SCHEMBL1105475 | 0.83 | EGFR (0.51) | EGFRIMPDH2ARBAZ1ACSNK2A1 | |
| SCHEMBL6768809 | 0.82 | EGFR (0.51) | EGFRIMPDH2ARBAZ1ANOTUM | |
| SCHEMBL28063529 | 0.80 | EGFR (0.49) | EGFRCSNK2A2CSNK2BIMPDH2BAZ1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269731-A | KIF18A inhibitors | 美国安进公司 | 2022-04-01 | — | — | CN | claimed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| CN-105658655-B | Thieno [2,3-c] pyrans as CFTR conditioning agents | 加拉佩格斯股份有限公司 | 2018-11-13 | — | — | CN | claimed |
| CN-108794474-A | Rutaecarpin derivative and its preparation method and application with multiple target point antitumor activity | 中国人民解放军第二军医大学 | 2018-11-13 | — | — | CN | claimed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2010059549-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | claimed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| EP-4313308-A1 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1362048-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002064595-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| CN-1348763-A | Medicine composite for preventing or treaitng diseases relating to IL-12 over growth | WARNER LAMBERT CO (US) | 2002-05-15 | — | — | CN | disclosed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | EGFR 339/4885CSNK2A2 138/4885CSNK2B 401/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | EGFR 339/4885CSNK2A2 138/4885CSNK2B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.